How Will Proposed Changes To The Nice Highly Specialised Technology Evaluation Process Impact Patient Access To Innovative Drugs for Rare Diseases?
Abstract
Authors
L Nicholson DL Fountain L Longworth E Adkins
L Nicholson DL Fountain L Longworth E Adkins
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now